High-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiency

International Journal of Psychiatry in Clinical Practice

Volumn 8, Issue 3, 2004, Pages 191-195

  Haller Gloor, F ^a   Eap, Chin B ^b   Turgeon, Jacques ^c   Baumann, Pierre ^b  

^a Ctr de Neurosciences Psychiatriques ^*  (Switzerland)

^b DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

CYP2D6; Depression; Enantiomers; Non response, lithium; Pharmacogenetics; Plasma concentrations; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D6; DESVENLAFAXINE; DRUG METABOLITE; LITHIUM; VENLAFAXINE;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SELECTIVITY; DRUG TOLERABILITY; ENANTIOMER; ENZYME DEFICIENCY; FEMALE; GENOTYPE; HUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; STEADY STATE; SYMPTOMATOLOGY;

EID: 6044223415     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500410005559     Document Type: Article

References (20)

1. Kirchheiner J, Brøsen K, Dahl ML et al (2001) CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 104: 173-92.
2. Le Bloc'h Y, Woggon B, Weissenrieder H et al (2003) Routine therapeutic drug monitoring in patients treated with 10-360 mg/day citalopram. Ther Drug Monit 25: 600-8.
3. Briley M (1998) Specific serotonin and noradrenaline reuptake inhibitors (SNRIs). A review of their pharmacology, clinical efficacy and tolerability. Hum Psychopharmacol Clin Exp 13: 99-111.
4. Fogelman SM, Schmider J, Venkatakrishnan K et al (1999) O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 20: 480-90.
5. Otton SV, Ball SE, Cheung SW et al (1996) Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 41: 149-56.
6. Lessard E, Yessine MA, Hamelin BA et al (1999) Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 9: 435-43.
7. Holliday SM, Benfield P (1995) Venlafaxine - a review of its pharmacology and therapeutic potential in depression. Drugs 49: 280-94.
8. Veefkind AH, Haffmans PMJ, Hoencamp E (2000) Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 22: 202-8.
9. Eap CB, Bertel-Laubscher R, Zullino D et al (2000) Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report. Pharmacopsychiatry 33: 112-5.
10. Eap CB, Lessard E, Baumann P et al (2003) Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 13: 39-47.
11. Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336: 529-32.
12. Griese E-U, Zanger UM, Brudermanns U et al (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8: 15-26.
13. Ciusani E, Zullino DF, Eap CB, Brawand-Amey M, Brocard M, Baumann P (2004) Combination therapy with venlafaxine and carbamazepine in depressive patients non-responding to venlafaxine: pharmacokinetic and clinical aspects. J Psychopharmacol (in press).
14. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25: 871-80.
15. Beique JC, De Montigny C, Blier P et al (1999) Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. Synapse 32: 198-211.
16. Mekler G, Woggon B (1997) A case of serotonin syndrome caused by venlafaxine and lithium. Pharmacopsychiatry 30: 272-3.
17. Zullino D, Preisig M, Baumann P (2001) Lithium augmentation in venlafaxine-refractory depression. J Clin Psychopharmacol 21: 242-3.
18. Hoencamp E, Haffmans J, Dijken WA et al (2000) Lithium augmentation of venlafaxine: an open-label trial. J Clin Psychopharmacol 20: 538-43.
19. Kennedy SH, McCann SM, Masellis M et al (2002) Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 63: 181-6.
20. Khalifa M, Daleau P, Turgeon J (1999) Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 291: 280-4.